Palliative therapy of disseminated malignant melanoma: A systematic review of 41 randomised clinical trials

Lancet Oncology

Volumn 4, Issue 12, 2003, Pages 748-759

  Eigentler, Thomas K ^a   Caroli, Ulrich M ^a   Radny, Peter ^a   Garbe, Claus ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; BLEOMYCIN; CARMUSTINE; CHLORPROMAZINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DETORUBICIN; HYDROXYUREA; INTERLEUKIN 2; LEVAMISOLE; LOMUSTINE; PROCARBAZINE; TAMOXIFEN; TEMOZOLOMIDE; VINCRISTINE; VINDESINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL STUDY; CLINICAL TRIAL; DISSEMINATED CANCER; DOSE RESPONSE; DRUG TOLERABILITY; HUMAN; IMMUNOSTIMULATION; MELANOMA; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0347503603     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(03)01280-4     Document Type: Review

References (70)

1. Radny P, Caroli UM, Bauer J, et al. Phase II trial of intralesional therapy with interleukin-2 in soft tissue melanoma metastases. Br J Cancer 2003; 89: 1620-26.
2. Armstrong BK, Kricker A. Cutaneous melanoma. Cancer Surv 1994; 19-20: 219-40.
3. MacKie RM, Bray CA, Hole DJ, et al. Incidence of and survival from malignant melanoma in Scotland: an epidemiological study. Lancet 2002; 360: 587-91.
4. MacLennan R, Green AC, McLeod GR, Martin NG. Increasing incidence of cutaneous melanoma in Queensland, Australia. J Natl Cancer Inst 1992; 84: 1427-32.
5. Ahmed I. Malignant melanoma: prognostic indicators. Mayo Clin Proc 1997; 72: 356-61.
6. Garbe C, Buttner P, Bertz J, et al. Primary cutaneous melanoma: identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer 1995; 75: 2484-91.
7. Miller B, Ries L, Hankey B, Kosary C, Edwards B. Cancer statistics review: 1973-1989. Bethesda: US Department of Health and Human Services, 1992: 92-278.
8. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 1995; 181: 193-201.
9. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622-3634.
10. Guerry D, Schuchter LM. Disseminated melanoma: is there a new standard therapy? N Engl J Med 1992; 327: 560-61.
11. Schadendorf D. Is there a standard for the palliative treatment of melanoma? Onkologie 2002; 25: 74-76.
12. Sun W, Schuchter LM. Metastatic melanoma. Curr Treat Options Oncol 2001; 2: 193-202.
13. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 2001; 134: 657-62.
14. Jelic S, Babovic N, Kovcin V, et al. Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study. Melanoma Res 2002; 12: 91-98.
15. Moon JH, Gailani S, Cooper MR, et al. Comparison of the combination of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and vincristine with two dose schedules of 5-(3,3-dimethyl-1-triazino) imidazole 4-carboxamide (DTIC) in the treatment of disseminated malignant melanoma. Cancer 1975; 35: 368-71.
16. Carter RD, Krementz ET, Hill GJ, et al. DTIC (nsc-45388) and combination therapy for melanoma: I, studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065). Cancer Treat Rep 1976; 60: 601-09.
17. Luikart SD, Kennealey GT, Kirkwood JM. Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. J Clin Oncol 1984; 2: 164-68.
18. Chauvergne J, Bui NB, Cappelaere P, et al. [Chemotherapy in advanced malignant melanoma: results of a controlled trial comparing a combination of dacarbazine (DTIC) and detorubicin with dacarbazine alone.] Sem Hop 1982; 58: 2697-701.
19. Ringborg U, Rudenstam CM, Hansson J, et al. Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: a randomized phase II study. Med Oncol Tumor Pharmacother 1989; 6: 285-89.
20. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17: 2745-51.
21. Chiarion-Sileni V, Nortilli R, Aversa SM, et al. Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. Melanoma Res 2001; 11: 189-96.
22. McKelvey EM, Luce JK, Vaitkevicius VK, et al. Bis chloroethyl nitrosourea, vincristine, dimethyl triazeno imidazole carboxamide and chlorpromazine combination chemotherapy in disseminated malignant melanoma. Cancer 1977; 39: 5-10.
23. Wittes RE, Wittes JT, Golbey RB. Combination chemotherapy in metastatic malignant melanoma: a randomized study of three DTIC-containing combination. Cancer 1978; 41: 415-21.
24. Jungnelius U, Ringborg U, Aamdal S, et al. Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma: a randomised phase III trial. Eur J Cancer 1998; 34: 1368-74.
25. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18: 158-66.
26. Middleton MR, Lorigan P, Owen J, et al. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer 2000; 82: 1158-62.
27. Cocconi G, Bella M, Calabresi F, et al. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 1992; 327: 516-23.
28. Rusthoven JJ, Quirt IC, Iscoe NA, et al. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol 1996; 14: 2083-90.
29. Creagan ET, Suman VJ, Dalton RJ, et al. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J Clin Oncol 1999; 17: 1884-90.
30. Agarwala SS, Ferri W, Gooding W, Kirkwood JM. A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma. Cancer 1999; 85: 1979-84.
31. Cocconi G, Passalacqua R, Foladore S, et al. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen, or vindesine plus tamoxifen: a prospective randomized study. Melanoma Res 2003; 13: 73-79.
32. Clunie GJ, Gough IR, Dury M, Furnival CM, Bolton PM. A trial of imidazole carboxamide and corynebacterium parvum in disseminated melanoma: clinical and immunologic results. Cancer 1980; 46: 475-79.
33. Costanzi JJ, Al-Sarraf M, Groppe C, et al. Combination chemotherapy plus BCG in the treatment of disseminated malignant melanoma: a Southwest Oncology Group study. Med Pediatr Oncol 1982; 10: 251-58.
34. Veronesi U, Aubert C, Bajetta E, et al. Controlled study with imidazole carboxamide (DTIC), DTIC + bacillus Calmette-Guerin (BCG), and DTIC + corynebacterium parvum in advanced malignant melanoma. Tumori 1984; 70: 41-48.
35. Costanzi JJ, Fletcher WS, Balcerzak SP, et al. Combination chemotherapy plus levamisole in the treatment of disseminated malignant melanoma: a Southwest Oncology Group study. Cancer 1984; 53: 833-36.
36. Jones AL, O'Brien ME, Lorentzos A, et al. A randomised phase II study of carmustine alone or in combination with tumour necrosis factor in patients with advanced melanoma. Cancer Chemother Pharmacol 1992; 30: 73-76.
37. Agarwala SS, Glaspy J, O'Day SJ, et al. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol 2002; 20: 125-33.
38. Falkson CI, Falkson G, Falkson HC. Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 1991; 9: 1403-08.
39. Thomson DB, Adena M, McLeod GR, et al. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. Melanoma Res 1993; 3: 133-38.
40. Bajetta E, Di Leo A, Zampino MG, et al. Multicenter randomized trial of dacarbazine alone or in ombination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol 1994; 12: 806-11.
41. Falkson CI. Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma. Med Oncol 1995; 12: 35-40.
42. Young AM, Marsden J, Goodman A,et al. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma. Clin Oncol 2001; 13: 458-65.
43. Falkson CI, Ibrahim J, Kirkwood JM, et al. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998; 16: 1743-51.
44. Sparano JA, Fisher RI, Sunderland M, et al. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 1993; 11: 1969-77.
45. Dorval T, Negrier S, Chevreau C, et al. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study. Cancer 1999; 85: 1060-66.
46. Sertoli MR, Queirolo P, Bajetta E, et al. Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. Melanoma Res 1999; 9: 503-09.
47. Hauschild A, Garbe C, Stolz W, et al. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Br J Cancer 2001; 84: 1036-42.
48. Flaherty LE, Atkins M, Sosman J, et al. Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials. J Clin Oncol 2001; 19: 3194-202.
49. Legha SS, Ring S, Papadopoulos N, et al. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer 1989; 64: 2024-29.
50. Legha SS, Ring S, Bedikian A, et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol 1996; 7: 827-35.
51. Eton O, Legha SS, Beclikian AY, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002; 20: 2045-52.
52. Johnston SR, Constenla DO, Moore J, et al. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma. Br J Cancer 1998; 77: 1280-86.
53. Atzpodien J, Neuber K, Kamanabrou D, et al. Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). Br J Cancer 2002; 86: 179-84.
54. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999; 17: 968-75.
55. Ridolfi R, Chiarion-Sileni V, Guida M, et al. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol 2002; 20: 1600-07.
56. Keilholz U, Goey SH, Punt CJ, et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group J Clin Oncol 1997; 15: 2579-88.
57. Crosby T, Fish R, Coles B, Mason MD. Systematic treatments for metastatic cutaneous melanoma (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software.
58. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7-17.
59. Grob JJ, Dreno B, de la Salmoniere P, et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. Lancet 1998; 351: 1905-10.
60. Richards JM, Gale D, Mehta N, Lestingi T. Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma. J Clin Oncol 1999; 17: 651-57.
61. Atzpodien J, Lopez HE, Kirchner H, et al. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen. Eur J Cancer 1995; 31A: 876-81.
62. Huncharek M, Caubet JF, McGarry R. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 2001; 11: 75-81.
63. Parmiani G, Castelli C, Dalerba P, et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst 2002; 94: 805-18.
64. Thurner B, Haendle I, Roder C, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190: 1669-78.
65. Schuler-Thurner B, Schultz ES, Berger TG, et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 2002; 195: 1279-88.
66. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328-32.
67. Jansen B, Schlagbauer-Wadl H, Brown BD, et al. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 1998; 4: 232-34.
68. Castel S, Pagan R, Mitjans F, et al. RGD peptides and monoclonal antibodies, antagonists of alpha(v)-integrin, enter the cells by independent endocytic pathways. Lab Invest 2001; 81: 1615-26.
69. Kumar CC, Armstrong L, Yin Z, et al. Targeting integrins alpha v beta 3 and alpha v beta 5 for blocking tumor-induced angiogenesis. Adv Exp Med Biol 2000; 476: 169-80.
70. John A, Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 2001; 7: 14-23.